Metagenomi Therapeutics to present preclinical data supporting MGX-001, a potential one-time therapy for hemophilia A, in oral presentation at 68th American Society of Hematology Annual Meeting. MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) - Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Dr. Alan Brooks, Senior Vice President of Research at the Company, will deliver an oral presentation on preclinical data supporting MGX-001 at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana. The presentation will highlight preclinical data on MGX-001, including the Company's most recent efficacy and safety results. MGX-001 is the Company's lead program in hemophilia A, and, subject to regulatory clearance, the Company plans to initiate a global clinical trial in 2027. Presentation details are as follows: Title: In vivo targeted FVIII gene integration demonstrating pre-clinical safety, efficacy and durability supporting development of a one-time therapy for hemophilia A Abstract: 952 Session: Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology Presentation Time: Monday, December 14, 2026, 2:45pm CT "Presenting MGX-001 in an oral session at ASH puts our preclinical data in front of the hematology community that understands the potential of our significantly differentiated profile for a one-time treatment in hemophilia A. The totality of the MGX-001 preclinical data supports our intent to initiate a global clinical trial in 2027 subject to regulatory approval," said Jian Irish, President and CEO of Metagenomi Therapeutics. "MGX-001 is designed to insert a Factor VIII gene site-specifically in the albumin locus to drive sustained production of Factor VIII from a single treatment, a novel approach to treating hemophilia A that is mechanistically distinct from prior gene therapy for this disease. The data we will present on efficacy, durability and safety reinforces our conviction that MGX-001 has the potential to free people with hemophilia A, including both adults and children, from a lifetime of treatment burden and the risk of bleeding events and joint damage that remain with currently available therapies." About Metagenomi Therapeutics Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction. MGX-001, the Company's lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/. Media Contact: Michael Fitzhugh LifeSci Communications [email protected]

Metagenomi Therapeutics, Inc. to present at the Wells Fargo 21st Annual Healthcare Conference. MWN-AI** Summary. Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a pioneering in vivo genome editing firm that specializes in developing curative genetic medicines by leveraging its proprietary technologies. Founded on the principles of metagenomics - an exploration of genetic materials from natural environments - the company is advancing a range of innovative CRISPR gene-editing tools aimed at rectifying a variety of genetic mutations in the human genome. Under the leadership of President and CEO Jian Irish, Ph.D., M.B.A., Metagenomi focuses on developing high-value programs targeting diseases with well-established biology and clear regulatory pathways. The company's flagship development program, MGX-001, aims to treat hemophilia A and has shown promising preclinical results, offering the potential for best-in-class treatment. This one-time therapy is designed for targeted genome editing and sustained gene expression, promising lifelong protection from bleeding events and joint damage in patients. Metagenomi's strategic focus also includes expanding its pipeline through its proprietary genetic editing technologies, which encompass site-specific deletion, insertion, and correction. In addition to hemophilia A, the company is exploring other indications using the MGX-001 genome integration system and is developing partnerships to address cardiometabolic diseases. Metagenomi is set to participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, Massachusetts, on September 10, 2026. The presentation will be available for viewing on the company's website. As Metagenomi continues to innovate within the genetic medicine landscape, it aims to establish a new standard of care while providing transformative solutions for patients affected by genetic disorders. For more information, please visit their official website at https://metagenomi.co/. MWN-AI** Analysis. Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is poised for significant attention as it presents at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. As a pioneering company in in vivo genome editing, Metagenomi is leveraging its proprietary CRISPR technologies to develop curative genetic therapies, positioning itself as a strong player in the rapidly expanding biopharmaceutical sector. The company's upcoming presentation will likely highlight its lead program, MGX-001, which targets hemophilia A. With promising preclinical results suggesting best-in-class potential for durable gene expression through a single treatment, MGX-001 could redefine treatment standards in hemophilia management. The focus on clear regulatory pathways reinforces investor confidence, along with its strategy to expand into other high-value disease areas, including cardiometabolic conditions. Investors should be particularly attentive to the outcomes of ongoing and future trials, as well as any strategic partnerships that could enhance Metagenomi's research capabilities or market reach. The Company's foundation on metagenomics not only differentiates it from traditional genetic medicine firms but also suggests a robust pipeline leveraging innovative gene-editing technologies, which could attract collaborations and partnerships with larger pharmaceutical entities. As with any investment in biotech, risks remain prevalent, particularly around regulatory approvals and the unpredictable nature of clinical trial outcomes. However, if Metagenomi can successfully navigate these challenges, it may provide significant upside potential. In summary, investors looking for exposure to cutting-edge therapeutic modalities may find Metagenomi Therapeutics a compelling prospect, especially post-conference as more clarity on MGX-001's developmental path and the company's strategic initiatives emerge. Watching management's insights during the fireside chat will provide valuable context for future market actions. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 01, 2026 08:00:00 am EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) - Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at 12:45 p.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events. About Metagenomi Therapeutics Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction. MGX-001, the Company's lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/. FAQ**. How does Metagenomi Therapeutics Inc Com MGX plan to leverage its CRISPR gene-editing tools to enhance the efficacy of its pipeline programs beyond hemophilia A? Metagenomi Therapeutics Inc (MGX) plans to leverage its CRISPR gene-editing tools to enhance the efficacy of its pipeline programs by focusing on expanding applications in rare genetic diseases and other therapeutic areas, emphasizing safe and precise gene editing technologies. What specific disease indications is Metagenomi Therapeutics Inc Com MGX targeting next, and how will these align with its clinical development strategy? Metagenomi Therapeutics Inc. is currently focusing on advancing its gene-editing therapies for rare genetic diseases and neurodegenerative disorders, aligning this strategy with its goal of addressing unmet medical needs and driving progression through clinical trials. Can you elaborate on the expected timeline for clinical trials related to the MGX-001 program in hemophilia A and any potential partnership opportunities for Metagenomi Therapeutics Inc Com MGX? As of now, Metagenomi Therapeutics anticipates initiating clinical trials for the MGX-001 program in hemophilia A in late 2024, with potential partnership opportunities likely emerging as they progress through trial phases and validate therapeutic efficacy. How does Metagenomi Therapeutics Inc Com MGX intend to differentiate its gene-editing technologies from competitors in the rapidly evolving landscape of genetic medicine? Metagenomi Therapeutics Inc Com MGX aims to differentiate its gene-editing technologies by focusing on the development of novel, highly specific gene-editing tools that offer greater precision, efficiency, and safety compared to existing solutions in the genetic medicine landscape. **MWN-AI FAQ is based on asking OpenAI questions about Metagenomi Therapeutics Inc Com (NASDAQ: MGX).